Dr. Zhao Mingfeng

Education

• 1990–1995: Bachelor's Degree in Clinical Medicine, Weifang Medical University
• 1997–2002: Doctor of Medicine (M.D.), Internal Medicine, Peking Union Medical College, Chinese Academy of Medical Sciences

International Postdoctoral Training

• 2002–2003: Postdoctoral Fellow, National Institutes of Health (NIH), USA — research on hematopoietic stem cell gene therapy
• 2003–2005: Associate Research Fellow / Postdoctoral Fellow, Duke University Medical Center, USA — focused on immunotherapy for hematologic malignancies and cell signaling regulation

Professional Appointments

Since 2005, Dr. Zhao has served in the Department of Hematology at Tianjin First Central Hospital, progressing from Deputy Director to Department Head, and currently serves as Director of Hematology. He has led the department's clinical hematology practice for more than 20 years, taking full responsibility for building the department's hematopoietic stem cell transplantation and CAR-T cell immunotherapy systems. As a BIOOCUS Medical Group partner and Transplant Director, he continues to advance access to advanced cellular therapies for patients with complex blood cancers.

Honors & Distinctions

• First-Tier Awardee, Tianjin "131" Innovative Talent Program
• Inaugural "Jinmen Medical Talent" Award, Tianjin
• Two-time recipient, Tianjin Science and Technology Progress Award (First Contributor)

Academic & Professional Memberships

• Committee Member, Hematopoietic Stem Cell Transplantation Group, Chinese Society of Hematology, Chinese Medical Association; Standing Committee Member, Tianjin Branch
• National Committee Member, Hematology Physicians Branch, Chinese Medical Doctor Association; Standing Committee Member, Tianjin Branch
• Chairman, Cell Therapy Committee, Tianjin Society of Hematology and Regenerative Medicine
• Vice Chairman, Tianjin Lymphoma Committee, China Anti-Cancer Association; Expert Committee Member, China MDS/MPN Collaborative Group; Vice President, Beijing-Tianjin-Hebei Integrated Traditional Chinese and Western Medicine Hematology Alliance; and more than ten additional national- and municipal-level academic positions

Areas of Clinical Expertise

• Standardized diagnosis and treatment of complex, high-risk hematologic malignancies, including acute and chronic leukemia, lymphoma, multiple myeloma, myelodysplastic syndrome (MDS), and aplastic anemia
• Fully-matched and haploidentical (half-matched) allogeneic hematopoietic stem cell transplantation, as well as autologous hematopoietic stem cell transplantation
• CAR-T cell immunotherapy, including post-transplant prophylactic CAR-T cell infusion and CAR-T treatment for relapsed/refractory hematologic malignancies
• Targeted, individualized precision therapy for hematologic malignancies, and post-transplant relapse prevention and management systems

Research Achievements

Dr. Zhao has led more than 10 provincial- and ministerial-level or higher research projects, including grants from the National Natural Science Foundation of China and key Tianjin municipal research programs. He has published over 140 papers, including more than 50 in SCI-indexed journals such as Blood, Leukemia, Haematologica, and Clinical Cancer Research, with a cumulative impact factor exceeding 400. His team was among the first in China to report that post-transplant targeted combination regimens reduce relapse in high-risk myeloid malignancies, and that post-transplant prophylactic CAR-T infusion reduces relapse in B-cell acute lymphoblastic leukemia — findings published in international journals including Leukemia.

Transplantation Program & Case Volume

Under Dr. Zhao's leadership, the department performed its first sibling-matched allogeneic transplant in 2008, and in 2015 he spearheaded the launch of haploidentical (half-matched) transplantation, making the center one of the few in Tianjin with full qualification to perform haploidentical transplants. The department has since completed several hundred hematopoietic stem cell transplants in total, spanning autologous, fully-matched allogeneic, haploidentical, and third-party cord-blood-assisted transplants. Haploidentical transplantation — the department's core signature technique — had reached nearly 50 cases by 2019 and continues to expand in scale each year.